341 100 Pill - orange round, 10mm
Pill with imprint 341 100 is Orange, Round and has been identified as Lamotrigine Extended-Release 100 mg. It is supplied by Torrent Pharmaceuticals Limited.
Lamotrigine is used in the treatment of Bipolar Disorder; Lennox-Gastaut Syndrome; Epilepsy; Seizure Prevention; Seizures and belongs to the drug class triazine anticonvulsants. Risk cannot be ruled out during pregnancy. Lamotrigine 100 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for 341 100
Lamotrigine Extended-Release
- Imprint
- 341 100
- Strength
- 100 mg
- Color
- Orange
- Size
- 10.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Triazine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Torrent Pharmaceuticals Limited
- National Drug Code (NDC)
- 13668-0341
- Inactive Ingredients
-
diethyl phthalate,
ferric oxide red,
ferric oxide yellow,
hypromellose 2910 (6 mPa.s),
hypromellose phthalate (31% phthalate, 40 cst),
lactose monohydrate,
magnesium stearate,
polyethylene glycol 400,
magnesium silicate,
titanium dioxide
Note: Inactive ingredients may vary.
Related images for "341 100"
More about lamotrigine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,765)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: triazine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Lamotrigine drug information
- Lamotrigine Chewable Dispersible Tablets
- Lamotrigine Orally Disintegrating Tablets
- Lamotrigine Extended-Release Tablets
- Lamotrigine Tablets
Other brands
Lamictal, Lamictal XR, Subvenite, Lamictal CD, Lamictal ODT
Professional resources
- Lamotrigine monograph
- Lamotrigine (FDA)
- Lamotrigine Chewable Tablet (FDA)
- Lamotrigine Extended Release Tablet (FDA)
- Lamotrigine ODT (FDA)
- Lamotrigine Tablets (FDA)
Other brands
Lamictal, Lamictal XR, Subvenite
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
